Navigation Links
The PASCAL Dynamic Contour Tonometer

ProductsThe PASCAL Dynamic Contour Tonometer
Company SMT Swiss Microtechnology AG
Item The PASCAL Dynamic Contour Tonometer
Features 
  • Slitlamp-mounted - same easy operation as the familiar applanation tonometer.
  • Convenient disposable tip prevents contamination and potential infection.
  • Direct measurement of pressure - no systematic errors from force-to-pressure conversion.
  • Numerical display of result - avoids operator bias and reading errors.
  • No mechanical calibration required; self-calibrating.
  • Battery operated - no cabling.
  • Visual control of eye/tip interface through transparent SensorTip.
  • Single button operation.
Description PASCAL. A new device for ocular precision tonometry.

The PASCAL Dynamic Contour Tonometer (DCT) is a third-generation, digital, contact tonometer for ophthalmological applications. The slitlamp-mounted device furnishes a numeric output of intra-ocular pressure (IOP) and of ocular pulse amplitude (OPA) upon touching the cornea for a few seconds. It measures pulsatile IOP directly and continuously (dynamically).

Info SMT Swiss Microtechnology AG
Customer Service: +41 (0)32 332 70 52

Related medicine products :

1. PASCAL Dynamic Contour Tonometer
2. SB Charit Intervertebral Dynamic Disc Spacer
3. Xtrem Dynamic electrophysiology catheter
4. DJD II Dynamic Elbow Joint Distractor
5. OSStaple™ Dynamic Compression Staple
6. Procyon P2000SA Dynamic Binocular Pupillometer
7. Ossur® AFO Dynamic
8. Comfy™ Dynamic Elbow Torque Orthosis
9. BODI™ Dynamic Orthosis
10. Controlled Dynamic Stretch Knee Brace
11. syngoDynamics
CenterPointLock Stoma Cap
CenterPointLock Sterile Drainable Kits
CenterPointLock Non-Sterile Urostomy Kits
CenterPointLock Pre-Sized Convex FlexWear Skin Barrier
Medicine Products:
(Date:12/4/2008)... One of the most respected and innovative ...development of the minimal-incision arm lift techn...process. Vaser® LipoSelection combined with Dr...ioplasty gives patients better contours and virtua...pit – and the world of plastic surgery is ta...
(Date:12/4/2008)... The DRE Waveline ProVet , a multi-functi...perior monitoring performance, and has a crisp, fl...s) December 4, 2008 -- DRE Veterinary — a pr...ash; recently unveiled the DRE Waveline ProVet , ... many as eight colorful waveforms. The sleek Wavel...
(Date:12/4/2008)... Global provider of language services ma... Washington, D.C. (Vocus) Dece.... (LLE®) announced today the release of their ...ment and email translation , language proficiency...uage instruction. Organizations in every sector, ...
(Date:12/4/2008)... Drs. Samuel and Elenore Bogoch of Oncolab...ins, a new class of peptides in genomic proteins*,...in human cancer of different cell types. No cancer...ed to be quantitatively related to mortality rate....ember 4, 2008 -- Drs. Samuel and Elenore Bogo...
Breaking Medicine News(10 mins):Health News:Washington, DC Plastic Surgeon Pioneers New Minimal-Scarring Technique 2Health News:Washington, DC Plastic Surgeon Pioneers New Minimal-Scarring Technique 3Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 2Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 3Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 4Health News:LLE Launches New Website Promoting Over-the-Phone Interpretation, Translation, and Language Testing Services 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3
...tored surveillance for patients with colon and rec... cancer recurrence // compared to less aggressive ...itals. Researchers have found that an intensified ...tate increased the chances of early diagnosis of c...
...titute for Biotechnology are finding out the mecha...tain mice which had the capacity to resist bacteri...ce model to find out new therapeutic pathways whic...ections. Bacterial infections are the most common...
...oportions not only in the animal world but human w... wanting to visit // countries with bird flu like ...from doctors. At the moment the unanimous voice is... is an animal disease and not a problem for humans...
... from Hong Kong from buying poultry from southern ...consumed during the // ar New Year holiday. One se...g residents would ask vendors to kill and pluck th...through the customs. Hong Kong health authorities...
Other Medicine News:
(Date:12/3/2008)... demonstrating potential in newly diagnosed patien...featured in two oral sessions at ASH , , - ...ally transfused patients by significantly reducing...- New long-term data from major independent breast...urgery treatment strategy, Femara vs. tamoxifen ,...
(Date:12/3/2008)...ewswire/ -- Roche today announced that the U.S. Fo...her guidance on the requirements for the Biologics...umab), the first interleukin-6 (IL-6) receptor-inh...ent of adult patients with moderately to severely ... result of the FDA,s evolving Risk Evaluation and ...
(Date:12/3/2008)...ire-FirstCall/ -- Sangamo BioSciences, Inc.,(Nasd...de an update on milestones,achieved in 2008 and p...tor,and Analyst Briefing to be held in New York C... Sigma-Aldrich Corporation,s Research,Biotech Bus...potential of the,two companies, collaboration to ...
(Date:12/3/2008)...leviates long-term anemia and organ damage in mice..., MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire/...gene into mouse blood cells, scientists at St. Jud...kle cell disease pathology. In their studies, the ...entially no difference from normal mice. Although ...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3SEIU Launches Ad Campaign Opposing Corporate Raiders Plan to Buy Mich Nursing Homes 2782 1SEIU Launches Ad Campaign Opposing Corporate Raiders Plan to Buy Mich Nursing Homes 2782 2Rat Study Gets at Root of Nicotine Addiction 2780 1Rat Study Gets at Root of Nicotine Addiction 2780 2The American Red Cross Releases Book Devoted to Your Dogs Health Because Your Dog is Counting on You 2775 1The American Red Cross Releases Book Devoted to Your Dogs Health Because Your Dog is Counting on You 2775 2PA Advocates Ask President Bush What about the Kids 3F 3F 2770 1PA Advocates Ask President Bush What about the Kids 3F 3F 2770 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7